This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NovaBay Pharmaceuticals To Present At The 13th Annual BIO CEO & Investor Conference

CEO Dr. Ron Najafi to Provide Webcast Corporate Presentation

EMERYVILLE, Calif., Feb. 8, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective Aganocide ® compounds for the topical treatment and prevention of antibiotic-resistant infections, will present at the 13 th Annual BIO CEO & Investor Conference being held at the Waldorf Hotel in New York City. Dr. Ron Najafi, NovaBay's Chief Executive Officer, will address attendees on Tuesday, February 15, 2011 at 8:00 AM Eastern Time (5:00 AM Pacific Time).

Those interested in listening to Dr. Najafi's presentation can use the following link to access the webcast: http://www.veracast.com/webcasts/bio/ceoinvestor2011/19201323.cfm .

The replay will be available one hour after the event and will expire on May 15, 2011.

More information about the BIO CEO & Investor Conference is available at: http://www.bio.org/bioceo/About-BIO-CEO/ .

To arrange a meeting with NovaBay management, please contact Adam Holdsworth at 212-825-3210, or e-mail adam@investorrelationsgroup.com.

About NovaBay's Aganocide Compounds

NovaBay's Aganocide compounds are novel, synthetic N-chlorinated antimicrobial molecules specifically designed and developed to mimic the body's natural defense against infection. These topical compounds maintain biological activities while demonstrating improved stability over the naturally occurring N-chlorinated antimicrobial molecules. In preclinical testing, Aganocide compounds have been shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi. NovaBay's Aganocide compounds have the potential to deliver the same or better efficacy than topical antibiotics, and to address the growing problem of antibiotic resistance by employing a novel mechanism of action.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's Aganocide compounds are being developed for the topical treatment and prevention of a wide range of infections without causing bacterial resistance. The company is developing commercial opportunities in four distinct healthcare markets: dermatology, ophthalmology, urology and hospital infections. Each of these market segments contains indications that are poorly served or have no approved FDA treatments available, with multiple hundred-million to billion-dollar revenue opportunities. NovaBay's strategy is to address these markets either through partnerships and collaborations, or by building an internal organization to strategically market products when appropriate from a commercial standpoint. NovaBay has internal development programs aimed at addressing hospital infections, chronic non-healing wounds, urinary catheter blockage and encrustation (UCBE), and onychomycosis. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections, as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in impetigo, acne and other dermatological indications. For more information on NovaBay, visit: www.NovaBaypharma.com .

CONTACT: NovaBay Pharmaceuticals, Inc.
         Thomas J. Paulson, Chief Financial Officer
         510-899-8800
         tjpaulson@NovaBaypharma.com
         
         The Investor Relations Group
         Investor Relations:
         Adam Holdsworth
         212-825-3210
         adam@investorrelationsgroup.com
         
         Public Relations:
         Laura Colontrelle
         212-825-3210
         laura@investorrelationsgroup.com

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs